A New Treatment Option for Children The U.S. Food and Drug Administration (FDA) has officially approved Gazyva (obinutuzumab) for the treatment of adult and pediatric patients aged 2 years and older with idiopathic nephrotic syndrome (specifically steroid-sensitive nephrotic syndrome, steroid-dependent nephrotic syndrome, and steroid-resistant nephrotic syndrome). This milestone marks a significant step forward for families…